HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tadashi Mio Selected Research

OSI-420

9/2011Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
7/2010Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
5/2010Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tadashi Mio Research Topics

Disease

53Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2021 - 06/2006
22Neoplasms (Cancer)
11/2022 - 02/2006
17Lung Neoplasms (Lung Cancer)
11/2022 - 03/2006
10Neoplasm Metastasis (Metastasis)
12/2020 - 03/2010
7Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2019 - 05/2010
6Infections
11/2019 - 08/2011
6Adenocarcinoma of Lung
04/2018 - 02/2011
5Interstitial Lung Diseases (Interstitial Lung Disease)
01/2020 - 01/2007
4Communicable Diseases (Infectious Diseases)
11/2022 - 01/2019
4Adenocarcinoma
01/2017 - 01/2009
3Tuberculosis (Tuberculoses)
11/2022 - 03/2020
3Pneumonia (Pneumonitis)
12/2021 - 01/2018
3COVID-19
12/2021 - 10/2020
3Pleural Effusion (Pleural Effusions)
01/2020 - 09/2010
3Anorexia
01/2018 - 10/2011
2Pulmonary Tuberculosis
11/2022 - 12/2016
2Liver Diseases (Liver Disease)
12/2021 - 01/2009
2Neutropenia
07/2021 - 05/2012
2Lung Diseases (Lung Disease)
03/2020 - 09/2018
2Thymoma (Thymic Carcinoma)
01/2019 - 12/2013
2Chronic Obstructive Pulmonary Disease (COPD)
01/2019 - 05/2010
2Pulmonary Embolism
12/2018 - 08/2011
2Acute Kidney Injury (Acute Renal Failure)
11/2018 - 05/2014
2Malignant Mesothelioma
03/2016 - 07/2012
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2013 - 08/2012
2Diarrhea
07/2013 - 10/2011
2Febrile Neutropenia
05/2012 - 04/2011
2Chronic Kidney Failure (Chronic Renal Failure)
04/2011 - 05/2010
1Melanoma (Melanoma, Malignant)
01/2022
1Fatigue
12/2021
1Thrombocytopenia (Thrombopenia)
07/2021
1Disseminated Intravascular Coagulation
01/2021
1Osteonecrosis (Kienbock's Disease)
12/2020
1Granuloma
11/2019
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
07/2019
1Respiratory Insufficiency (Respiratory Failure)
07/2019
1B-Cell Lymphoma (Lymphoma, B Cell)
07/2019
1Hematologic Neoplasms (Hematological Malignancy)
01/2019

Drug/Important Bio-Agent (IBA)

22ErbB Receptors (EGF Receptor)IBA
11/2021 - 10/2006
15NivolumabIBA
12/2021 - 12/2016
12Gefitinib (Iressa)FDA Link
09/2012 - 01/2007
10Immune Checkpoint InhibitorsIBA
11/2022 - 12/2016
10Tyrosine Kinase InhibitorsIBA
11/2021 - 10/2008
8Erlotinib Hydrochloride (CP 358,774)FDA Link
07/2013 - 04/2010
5Pemetrexed (MTA)FDA Link
04/2018 - 03/2011
4Adrenal Cortex Hormones (Corticosteroids)IBA
07/2021 - 03/2006
4Carboplatin (JM8)FDA LinkGeneric
04/2018 - 05/2012
4Epidermal Growth Factor (EGF)IBA
09/2012 - 04/2010
3Interferon-gamma (Interferon, gamma)IBA
11/2022 - 11/2019
3pembrolizumabIBA
12/2021 - 01/2018
3osimertinibIBA
01/2021 - 01/2019
3Anaplastic Lymphoma KinaseIBA
01/2021 - 01/2017
3AntibodiesIBA
01/2020 - 01/2018
3GemcitabineFDA Link
03/2016 - 02/2011
3Pharmaceutical PreparationsIBA
07/2013 - 06/2009
3Irinotecan (Camptosar)FDA LinkGeneric
12/2012 - 04/2011
3OSI-420IBA
09/2011 - 05/2010
2SolutionsIBA
12/2021 - 01/2020
2Amino AcidsFDA Link
09/2018 - 06/2009
2Bevacizumab (Avastin)FDA Link
04/2018 - 08/2011
2Vinorelbine (Navelbine)FDA LinkGeneric
01/2018 - 05/2012
2nedaplatinIBA
12/2013 - 02/2011
2Docetaxel (Taxotere)FDA Link
12/2013 - 10/2010
2amrubicinIBA
12/2012 - 05/2010
2Insulin-Like PeptidesIBA
09/2012 - 10/2011
2Insulin-Like Growth Factor Binding Protein 3IBA
09/2012 - 10/2011
2PlatinumIBA
08/2012 - 11/2010
2Nitric Oxide (Nitrogen Monoxide)FDA Link
07/2012 - 11/2010
2Biomarkers (Surrogate Marker)IBA
10/2011 - 11/2008
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2011 - 10/2009
2Phosphotransferases (Kinase)IBA
11/2010 - 04/2010
2Codon (Codons)IBA
11/2010 - 06/2009
1remdesivirIBA
12/2021
1Filgrastim (Neupogen)FDA Link
07/2021
1Prednisolone (Predate)FDA LinkGeneric
07/2021
1Cyclooxygenase InhibitorsIBA
01/2021
1Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
01/2021
1Zoledronic Acid (Zometa)FDA Link
12/2020
1Bone Density Conservation AgentsIBA
12/2020
1DenosumabFDA Link
12/2020
1AlbuminsIBA
01/2020
1B7-H1 AntigenIBA
01/2020
1Anti-Idiotypic AntibodiesIBA
11/2019
1AcidsIBA
11/2019
11-dodecylpyridoxal (PLD)IBA
07/2019
1atezolizumabIBA
07/2019
1Anti-Infective Agents (Microbicides)IBA
01/2019
1Immunosuppressive Agents (Immunosuppressants)IBA
01/2019

Therapy/Procedure

15Therapeutics
11/2022 - 06/2006
15Drug Therapy (Chemotherapy)
07/2021 - 09/2010
10Immunotherapy
11/2022 - 12/2016
4Radiotherapy
01/2019 - 03/2006
3Chemoradiotherapy
01/2020 - 06/2006
3Retreatment
01/2020 - 01/2018
2Artificial Respiration (Mechanical Ventilation)
01/2019 - 05/2014
2Renal Dialysis (Hemodialysis)
04/2011 - 05/2010
1Nursing Care
01/2021
1Activities of Daily Living (ADL)
01/2021
1Treatment Delay
10/2020
1Aftercare (After-Treatment)
06/2020